US drugmakers Merck and Moderna said Wednesday an experimental melanoma drug that delivers treatment tailored to a patient’s specific tumor prevented the cancer from returning in a large clinical trial. Called “intismeran autogene,” it is based on the same messenger ribonucleic acid technology behind Covid-19 vaccines. Researchers have been working on developing mRNA treatments against […]
The post Merck and Moderna’s tailored cancer drug curbs melanoma recurrence in trial appeared first on Insider Paper.
